Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Judy Durgin v. Kevin W Sharer et al
Case Number:
2:07-cv-03001
Court:
Nature of Suit:
Multi Party Litigation:
Derivative Litigation
Judge:
Firms
Companies
Sectors & Industries:
-
January 10, 2017
Amgen Beats Decade-Old Investor Suit Over Off-Label Scheme
A California judge Tuesday dismissed a decade-old action claiming Amgen Inc.'s board caused more than $1 billion in damages by overseeing an off-label drug marketing scheme, saying the shareholder failed to make a demand on the officials to instigate litigation before filing her suit.
-
January 09, 2017
Amgen Argues Decade-Old Derivative Suit Still Lacks Facts
Amgen Inc. told a California judge Monday that a decade-old action claiming the company's board caused more than $1 billion in damages by overseeing an off-label marketing scheme lacked facts to support "conclusory allegations" and should be tossed not "supplemented" as the shareholder plaintiffs suggested.
-
November 17, 2016
Amgen Investor Defends Decade-Old Derivative Suit
An Amgen Inc. shareholder told a California federal court Wednesday that she didn't need to make a demand for litigation before bringing her now-reopened, 9-year-old action against the company's officers and directors alleging they caused more than $1 billion in damages by overseeing an off-label marketing scheme.